SQI Diagnostics Inc. to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT

Rhea-AI Summary

SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF) announces CEO Andrew Morris will present at the 2022 Virtual Growth Conference from March 28-30, 2022, 9:00 a.m. to 5:00 p.m. EDT. This event, hosted by Maxim Group LLC and M-Vest, features executives from various sectors including Biotech and Healthcare. Attendees can participate in discussions and live Q&A sessions. SQI specializes in respiratory health and precision medicine tests, enhancing COVID-19 monitoring and organ transplant informatics. For more details, visit www.sqidiagnostics.com.

TORONTO, March 25, 2022 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests, announced today that Company CEO Andrew Morris has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30^th from 9:00 a.m. - 5:00 p.m. EDT.

Sign up here to access the presentation

During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITS, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/ Media/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.

This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.

Click Here to Reserve your seat

About SQI Diagnostics

SQI Diagnostics is a leader in the science of lung health. The Company develops and manufactures respiratory health and precision medicine tests that run on SQI's fully automated systems. The Company's tests simplify and improve COVID19 antibody monitoring, Rapid Acute Lung Injury testing, donor organ transplant informatics, and immunological protein and antibody testing. SQI Diagnostics is driven to create and market life-saving testing technologies that help more people in more places live longer, healthier lives. For more information, please visit www.sqidiagnostics.com.

FORWARD-LOOKING INFORMATION

This press release contains certain words and statements, which may constitute "forward-looking statements" within the meaning of applicable securities laws relating to future events or future performance and reflect the current expectations and assumptions of the Company regarding its growth, results of operations, performance, business prospects and opportunities. These statements generally can be identified by use of forward-looking words such as "may", "would", "could", "will", "should", "expect", "plan", "estimate", "anticipate", "intends", "believe", "potential", or "continue" or the negative thereof or similar variations. The Company's actual results and performance discussed herein could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, the effect of the global pandemic and consequent economic disruption, and the factors detailed in the Company's ongoing filings with the securities regulatory authorities, available at www.sedar.com.

Although the forward-looking statements contained herein are based on what we consider to be reasonable assumptions based on information currently available to us, there can be no assurance that actual events, performance or results will be consistent with these forward-looking statements, and our assumptions may prove to be incorrect. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:

Chief Financial Officer
Morlan Reddock
416.674.9500 ext. 277
mreddock@sqidiagnostics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/sqi-diagnostics-inc-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim-group-llc-and-hosted-by-m-vest-on-march-28th---30th-from-900-am---500-pm-edt-301511049.html

SOURCE SQI Diagnostics Inc.

FAQ

What is the date of the 2022 Virtual Growth Conference for SQI Diagnostics?

The 2022 Virtual Growth Conference will take place from March 28 to March 30, 2022.

Who will represent SQI Diagnostics at the Virtual Growth Conference?

CEO Andrew Morris will represent SQI Diagnostics at the conference.

What are the conference hours for the SQI Diagnostics presentation?

The conference will run from 9:00 a.m. to 5:00 p.m. EDT each day.

How can I attend the Virtual Growth Conference featuring SQI Diagnostics?

You can attend by signing up to become an M-Vest member.

What sectors will be featured at the 2022 Virtual Growth Conference?

Sectors include Biotech, Clean Energy, Electric Vehicles, Healthcare, and more.